Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT

This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.

Participants needed: 266
Trial details
Age: 14-60Biological sex: AllType: InterventionalSponsor: Yi ZhangUpdated: Mar 12, 2026Locations: 4
Eligibility criteria

Patients are fully aware of the study, participate voluntarily and sign the info... [+2]

refuse to participate in this clinical study; [+2]

Status: Recruiting

Genetically Modified T Cells Treating Malignant Tumors

To observe the safety, tolerability and initial effectiveness of gene modified T cell therapy in patients with malignant tumors in First Affiliated Hospital of Zhengzhou University, China.

Participants needed: 100
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Yi ZhangUpdated: Sep 25, 2024Locations: 1
Eligibility criteria

Subjects with malignant tumors confirmed by histopathology or cytology, includin... [+8]

Received anti-PD1, anti-PD-L1 or anti-PD-L2 antibody therapy or other immunother... [+11]